Tom Wickham
Chief Scientific Officer GentiBio
Tom Wickham, Ph.D., is Chief Scientific Officer at GentiBio with over 30 years of experience advancing cellular, gene, immuno-biologic, and liposomal therapies from discovery through clinical development. Previously, he was SVP of R&D at Rubius Therapeutics, where he built discovery and preclinical teams and advanced multiple INDs using engineered red cell therapies. He also held leadership roles at Merrimack Pharmaceuticals, EMD Lexigen (now Merck-Serono), and GenVec. Tom earned his B.S. in Chemical/Biomedical Engineering from Carnegie Mellon, Ph.D. in Biochemical Engineering from Cornell, and completed postdoctoral training in Immunology at The Scripps Research Institute.
Seminars
Join this session for a candid conversation with experts pursuing the reality of of-the-shelf cell therapies:
- Discussing the advantages of using allogeneic approaches over autologous approaches to make immune resetting scalable for large autoimmune patient populations
- Focusing on necessary gene-editing strategies and conditioning regimens to eliminate the risk of graft vs host disease and other safety concerns
- Deep diving into current indications being explored for allogeneic cell therapy
